Eingun James Song, MD, is the director of clinical research for Frontier Dermatology.
Experts discuss the evolving management of psoriatic arthritis, emphasizing that while current treat-to-target guidelines prioritize controlling inflammation over structural damage, integrating advanced imaging for earlier detection and advocating for structural damage assessment as a key outcome could enhance long-term patient outcomes amid expanding therapeutic options.
Experts discuss the structural and mechanistic differences between 2 IL-23 p19 inhibitors, exploring how variations in Fc region design may influence their localization to inflamed sites and clinical efficacy—particularly in preventing structural damage—and highlight challenges in assessing progression in psoriatic arthritis trials, suggesting that advanced imaging such as ultrasound could improve future evaluations.
Experts discuss recent clinical evidence confirming that IL-23 inhibitors effectively inhibit structural damage in psoriatic arthritis—particularly highlighted by the APEX trial’s findings in bio-naive patients—reinforcing their emerging role as a safe, convenient, and increasingly preferred first-line treatment for both joint and skin manifestations.
Experts discuss how treatment decisions in psoriatic arthritis increasingly balance current disease severity with long-term risk, highlighting the structural protection offered by TNF and IL-17 inhibitors, the growing preference for IL-17s in dermatology due to rapid efficacy and skin clearance, and the rising use of IL-23 inhibitors for their favorable safety, dosing convenience, and emerging joint efficacy—factors that are shaping more personalized and proactive therapeutic strategies.
Experts discuss how treatment decisions in psoriatic arthritis increasingly balance current disease severity with long-term risk, highlighting the structural protection offered by TNF and IL-17 inhibitors, the growing preference for IL-17s in dermatology due to rapid efficacy and skin clearance, and the rising use of IL-23 inhibitors for their favorable safety, dosing convenience, and emerging joint efficacy—factors that are shaping more personalized and proactive therapeutic strategies.
Experts discuss the complex immunopathology of psoriatic arthritis (PsA), highlighting the roles of IL-23, Th17 cells, and tissue-resident memory T cells in driving joint and skin inflammation and exploring how early, targeted intervention—particularly with IL-23 inhibitors—may control symptoms, alter disease progression, and promote lasting remission.
Experts discuss the complementary roles of imaging modalities in psoriatic arthritis assessment, noting the continued use of x-rays for tracking structural damage, the added value of ultrasound and MRI in detecting subclinical inflammation, and how advanced imaging supports proactive disease management despite practical limitations in routine care.
Experts discuss the challenges of psoriatic arthritis (PsA) screening in dermatology clinics, highlighting the limitations of current tools such as the Psoriasis Epidemiology Screening Tool (PEST) questionnaire, the potential of musculoskeletal ultrasound and artificial intelligence (AI)–assisted imaging to improve diagnostic accuracy and triage, and the opportunity for technology-enabled workflows to enhance early detection while easing pressure on rheumatology services.
Experts discuss the frequent delay in psoriatic arthritis (PsA) diagnosis that leads to irreversible joint damage, emphasizing the pivotal role of dermatologists in early detection, the value of screening tools and public education, and the potential of early systemic psoriasis treatment to reduce PsA risk. They highlight the need for proactive, collaborative care to prevent long-term disability.
Experts discuss the evolving role of dermatologists in the early detection and management of psoriatic arthritis (PsA), emphasizing the importance of recognizing high-risk features, initiating timely intervention—especially in underserved settings—and considering systemic therapies that may reduce joint damage and delay disease progression through proactive, collaborative care.
Experts discuss the profound impact of unchecked structural damage in psoriatic arthritis (PsA) on long-term physical function and quality of life, highlighting the predictive value of early joint damage, the importance of aligning treatment with individual functional goals, and the critical need for early detection—including of silent disease—through advanced imaging or regular monitoring.
Experts discuss the importance of early detection and treatment in psoriatic arthritis (PsA), emphasizing that structural damage often begins with subclinical inflammation detectable by advanced imaging—such as ultrasound and MRI—well before changes appear on x-rays, and highlighting how timely intervention can prevent irreversible joint destruction and improve long-term outcomes.
